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Se-Hwa Kim,d Daria Mochly-Rosen,c Sanjay Kumarab and Niren Murthy*ab
Aldehyde dehydrogenases (ALDHs) catalyze the oxidation of an aldehyde to a carboxylic acid and are
implicated in the etiology of numerous diseases. However, despite their importance, imaging ALDH
activity in cells is challenging due to a lack of fluorescent imaging probes. In this report, we present
a new family of fluorescent probes composed of an oligothiophene flanked by an aldehyde and an
electron donor, termed thiophene-bridged aldehydes (TBAs), which can image ALDH activity in cells. The
TBAs image ALDH activity via a fluorescence sensing mechanism based on the modulation of
intramolecular charge transfer (ICT) and this enables the TBAs and their ALDH-mediated oxidized
products, thiophene-bridged carboxylates (TBCs), to have distinguishable fluorescence spectra. Herein,
we show that the TBAs can image ALDH activity in cells via fluorescence microscopy, flow cytometry,
and in a plate reader. Using TBA we were able to develop a cell-based high throughput assay for ALDH
inhibitors, for the first time, and screened a large, 1460-entry electrophile library against A549 cells. We
identified a,b-substituted acrylamides as potent electrophile fragments that can inhibit ALDH activity in
cells. These inhibitors sensitized drug-resistant glioblastoma cells to the FDA approved anti-cancer drug,
temozolomide. The TBAs have the potential to make the analysis of ALDH activity in cells routinely
possible given their ability to spectrally distinguish between an aldehyde and a carboxylic acid.Introduction
Reactive aldehydes are produced in a wide variety of biochem-
ical pathways, ranging from ethanol metabolism to drug
detoxication pathways, and have a profound inuence on
human physiology and pathology.1,2 Aldehydes are mutagenic
and cytotoxic because they form addition products with DNA,
proteins, and other macromolecules. Therefore, their over-
production is implicated in the etiology of numerous
diseases, including cancer, inammatory diseases, diabetes,
cardiac ischemia, stroke, and neurodegenerative diseases.3–21 In
addition, reactive aldehydes also play a signicant role inCalifornia, 140 Hearst Memorial Mining
nmurthy@berkeley.edu
in Bioengineering, UC Berkeley, Berkeley,
iology, Stanford University, School of
d Science, 267 Gajeong-ro, Yuseong-gu,
tion (ESI) available. See DOI:
hemistry 2017inhibiting the development of cancer stem cells and in medi-
ating the toxic effects of cancer chemotherapeutics.
Aldehyde dehydrogenases (ALDHs) catalyse the oxidation of
an aldehyde into a carboxylic acid and play an essential role in
protecting cells against the toxic effects of aldehydes.3,4,9 ALDHs
are central regulators of cell physiology, and a wide number of
diseases are caused by dysregulation of ALDH activity. For
example, the down-regulation of ALDH activity has been
implicated in the etiology of numerous inammatory diseases,
such as alcohol induced liver toxicity, cardiac ischemia, and
Parkinson’s disease, and in these diseases the up-regulation of
ALDH is protective. The over-expression of ALDH activity can
also be problematic and is implicated in the development of
cancer and cancer drug resistance. In addition, ALDH activity is
necessary for the generation of stem cells and is currently one of
the most powerful biomarkers for identifying stem cells and
cancer stem cells.
There is therefore great interest in understanding the cell
biology of ALDHs and also in identifying small molecules that
can either up-regulate or down-regulate their activity.17,20,21 For
example, the over expression of ALDH1A1 causes drug resis-
tance in triple negative breast cancers and in glioblastomas,
and ALDH inhibitors have the potential to signicantly improve
the efficacy of chemotherapeutics.22–29 Similarly, down-Chem. Sci., 2017, 8, 7143–7151 | 7143
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View Article Onlineregulation of ALDH activity is implicated in the etiology of
numerous inammatory diseases, and compounds that can up-
regulate ALDH expression or its activity have the potential to
treat a wide variety diseases, including cardiac ischemia.
However, it has been challenging to develop small molecules
that can modulate the activity of ALDHs and also to understand
the regulation of ALDHs because uorescent dyes have not been
developed that can image ALDH activity in cells via uorescence
microscopy or in a plate reader format. Developing uorescent
dyes that can image ALDH activity has been challenging
because ALDHs catalyse the transformation of aldehydes to
carboxylic acids, and this conversion is not compatible with
conventional uorescent probe design strategies, such as frag-
mentation reactions, photo-induced electron transfer (PET),
and enhancement of pi-conjugation.30–36
ALDEFLUOR and its derivatives are the only class of uo-
rescent probe that can image ALDH activity in cells.37 ALDE-
FLUOR is composed of a BODIPY dye linked to an aldehyde, and
is oxidized into a carboxylic acid by cellular ALDHs, which
enhances its accumulation within cells, due to the negative
charge of the carboxylic acid. ALDEFLUOR has been extensively
used to identify stem cells via ow cytometry, and is currently
one of the best reagents available for identifying stem cells.
However, ALDEFLUOR does not change its uorescence aer
ALDH oxidation and consequently generates high levels of
background uorescence, and this signicantly limits its
potential applications outside of stem cell detection via ow
cytometry. For example, ALDEFLUOR is problematic to use for
imaging ALDH activity via a uorescence microscope or via
a plate reader, and consequently has not found applications as
a reagent for developing ALDH inhibitors or as a tool for
understanding the biology of ALDHs. In addition, ALDEFLUOR
reacts with all of the ALDHs and lacks isoenzyme specicity.37e
There is therefore considerable interest in developing ALDH
probes that change their uorescence aer ALDH oxidation.
Modulation of intramolecular charge transfer (ICT) has great
potential as a strategy for imaging ALDH activity. Because the
emission spectra of uorophores that generate ICT are very
sensitive to changes in electron donating or withdrawing groups.
In addition, aldehydes and carboxylic acids have signicantly
different electron withdrawing strengths, where the aldehyde is
a strong electron withdrawer (s ¼ 0.46) and the carboxylate is
a weak electron withdrawer (s ¼ 0). Modulation of ICT has been
used to develop uorescent probes that can detect ALDH, using
a naphthalene-based uorophore directly conjugated to an alde-
hyde.38 The naphthaldehydes are ALDH substrates and can
distinguish between carboxylic acid and aldehyde groups, due to
differences in their electron withdrawing strength. This class of
uorophore was able to measure ALDH activity in blood samples
and in saliva, and served as a platform for the development of
point of care diagnostics. However, the naphthaldehydes emit in
the 380–450 nm range and therefore did not nd widespread use
as a reagent for imaging ALDH in cell culture, due to the strong
background uorescence signal at these wavelengths. Conse-
quently, there is great interest in developing new ICT based uo-
rophores that can detect ALDH activity and also emit at
wavelengths that are suitable for cell culture imaging, 450–700 nm.7144 | Chem. Sci., 2017, 8, 7143–7151Oligothiophenes have the potential to act as uorophores
that can image ALDH activity in cells, due to their ability to
generate ICT in their excited state and their tunable emission
wavelengths, which span the 450–700 nm range. In addition,
Fin et al. have demonstrated that ICT based oligothiophenes
can distinguish between an aldehyde and a methyl ester,39
which suggests that oligothiophenes can potentially distinguish
between an aldehyde and a carboxylic acid, given the similar
electron withdrawing strength of a carboxylic acid and a methyl
ester. In addition, oligothiophenes are linear aromatic planar
molecules and have structural similarities to a variety of known
ALDH substrates such as substituted naphthaldehydes, and are
therefore good candidates to be ALDH substrates. However,
despite their promise, oligothiophenes have never been inves-
tigated as ALDH imaging probes.Results and discussion
Molecular design of the TBAs
In this report, we present a family of uorescent dyes, termed
thiophene-bridged aldehydes (TBAs), which can image ALDH
activity in cells. Themechanism by which the TBAs image ALDH
activity is shown in Fig. 1. The TBAs are push–pull uorophores
composed of a bisthiophene that is anked by an electron
withdrawing aldehyde and an electron donating group. In the
presence of ALDHs, the aldehydes of the TBAs are oxidized into
carboxylic acids, generating thiophene-bridged carboxylates
(TBCs), which have blue-shied uorescence in comparison to
the TBAs. The TBAs and their ALDH oxidation products, TBCs,
have different uorescence spectra because the TBAs generate
strong intramolecular charge transfer (ICT) in their excited
state, whereas the TBCs do not. The TBCs cannot generate ICT
in their excited state because their carboxylate has weak elec-
tron withdrawing ability (sigma¼ 0), and acts as a weak electron
acceptor. The oxidation of the TBAs into TBCs by cellular
ALDHs should be straightforward to visualize because their
different uorescence spectra will minimize interference from
background uorescence signals. In addition, the oxidation
products, termed TBCs, have emission maxima in the 450–
550 nm range, which are ideal wavelengths for imaging ALDH
in cells because of the low background uorescence at these
wavelengths.The TBAs and TBCs emit uorescence at different
wavelengths
To image ALDH activity in cells, the TBAs and TBCs need to
have distinguishable uorescence spectra. We synthesized four
different TBAs and their carboxylic analogues (TBCs), to deter-
mine if the TBAs could spectrally distinguish between an alde-
hyde and a carboxylic acid. Table 1 demonstrates that the TBAs
and TBCs have substantially different absorption and emission
properties. For example, the uorescence emissions of all four
TBAs were red-shied by approximately 70–120 nm from their
carboxylic acid analogues (see ESI, Fig. S15†). We investigated
the difference in uorescence emission between the TBAs and
TBCs, aer excitation at the TBC absorption maxima, toThis journal is © The Royal Society of Chemistry 2017
Fig. 1 (a) Thiophene-bridged aldehydes (TBAs) image ALDH activity in cells. The TBAs are a new family of fluorescent probes that can image
ALDH activity in cells. The TBAs are composed of a bisthiophene that is flanked by an aldehyde and an electron donating group (EDG). The TBAs
are internalized by cells and oxidized by ALDHs into carboxylic acids (termed TBCs). TBAs and TBCs have different emission wavelengths and the
oxidation of the TBAs by ALDHs can therefore be visualized in living cells. The TBAs can image ALDH activity in cells via fluorescencemicroscopy
and flow cytometry and in a plate reader. (b) The TBAs can screen chemical libraries in cells and identify ALDH inhibitors. We developed a high
throughput cell-based assay for identifying ALDH inhibitors using TBA2. A large, 1460-entry electrophile library was screened on A549 cells using
TBA2. We identified a,b-substituted acrylamides as lead electrophile fragments that can irreversibly inhibit ALDH. The a,b-substituted acryl-
amideswere able to sensitize glioblastoma stem cells to temozolomide and prevent drug resistance. The TBAs have great potential for enhancing
the development of new ALDH modulating drugs.
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View Article Onlinedetermine if there were sufficient differences between them to
enable cellular imaging of ALDHs. In addition, we also wanted
to identify the TBA that was best suited for ALDH imaging.
Table 1 demonstrates that TBA2 is the most effective TBA. TBC2
generated a 214 fold increase in emission at 520 nm, versus
TBA2, aer excitation at 420 nm, the TBC absorption maxima.Table 1 The fluorescence emission of the TBCs is blue shifted from the
TBAsa lex/lem
b TBCs (TBAs aer ALDH oxida
402/516
450/642
408/530
406/535
a Chemical structures of the TBAs. b Absorbance/uorescence emission m
uorescence emission maximum wavelength. e Fold changes in emission
This journal is © The Royal Society of Chemistry 2017The quantum yield of TBC2 in water was also measured and was
9%, which is comparable to cyanine dyes.40 We performed
density functional theory (DFT) calculations on TBA2 and TBC2,
to determine if their different emission wavelengths could be
explained by the modulation of intramolecular charge transfer
(ICT) in their excited states. ESI Fig. S16† demonstrates that theTBAs
tion)c lex/lem
d Fold changes in uorescence (ITBC/ITBA)lem(TBC)
e
370/446 4
420/520 214
378/460 22
370/445 30
aximum wavelength. c Chemical structures of the TBCs. d Absorbance/
when either TBA or TBC was excited at TBC’s absorption maximum.
Chem. Sci., 2017, 8, 7143–7151 | 7145
Fig. 2 The electron donating groups of the TBAs determine their reactivity and specificity towards ALDH catalyzed oxidation. (a and b) TBA1 and
TBA2 are pan-specific ALDH substrates; (c and d) TBA3 and TBA4 have specificity for ALDH1A1, ALDH3A1, and ALDH3A2.
Chemical Science Edge Article
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View Article OnlineLUMO of TBA2 has a dipole moment of 8.47D, whereas the
LUMO of TBC2 has a dipole moment of only 6.50D. These
experiments demonstrate that the different electron with-
drawing properties of an aldehyde and a carboxylic acid can be
visualized using push–pull bisthiophenes, and that TBAs have
the uorescence properties needed to image ALDH activity.Fig. 3 TBA2 can detect ALDH activity via flow cytometry and is more se
treated with PBS (yellow), TBA2 (red), and TBA2 + disulfiram (blue). Cell
treated with TBA2 + disulfiram. (b and c) Dot-plot representations of A54
A549 cells are ALDH positive. (d) Flow cytometry histograms of A549 ce
DEAB (violet). (e and f) Dot-plot representations of A549 cells treated w
ALDH positive.
7146 | Chem. Sci., 2017, 8, 7143–7151TBAs are substrates for ALDH-mediated oxidation
The ALDHs catalyze the oxidation of short chain aliphatic and
aromatic aldehydes, and it is unclear whether ALDHs can
oxidize conjugated oligo aromatic aldehydes. We therefore
investigated whether the TBAs were substrates for 8nsitive than ALDEFLUOR. (a) Flow cytometry histograms of A549 cells
s treated with TBA2 have a significantly higher fluorescence than cells
9 cells treated with TBA2 and TBA2 + disulfiram indicate that 92.4% of
lls treated with PBS (green), ALDEFLUOR (pink), and ALDEFLUOR and
ith ALDEFLUOR and ALDEFLUOR + DEAB indicate that only 3.03% are
This journal is © The Royal Society of Chemistry 2017
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View Article Onlinerecombinant human ALDHs; ALDH1A1, ALDH1A3, ALDH2,
ALDH3A1, ALDH3A2, ALDH4A1, ALDH5A1 and ALDH7A1, which
represent the better characterized ALDHs. ALDH-mediated
oxidation of the TBAs was determined by measuring the uores-
cence at the corresponding TBC’s emission wavelength (ESI,
Fig. S17†). Fig. 2 demonstrates that the TBAs are substrates for
these ALDHs, and that the isoform specicity of the TBAs is
determined by their electron donating group. For example, TBA2,
which has a diethylamine as its electron donating group, was
a substrate for all of the ALDHs tested, whereas TBA3, which has
a phenol as its electron donating group, was only a substrate for
ALDH1A1, ALDH3A1, and ALDH3A2. We selected TBA2 for future
ALDH imaging experiments because of its broad reactivity with the
ALDH isoforms, and because of its large change in uorescence
aer oxidation. The kcat/Km values of TBA2 for the 8 recombinant
ALDHs were determined and were in the range of 1.56  106 to
65.44  106 min1 M1 (see ESI Fig. S18 and Table S2†).
Although TBA2 is a pan-specic ALDH substrate, its rate of
oxidation is still approximately 3 orders of magnitude lower
than cellular aldehydes, such as acetaldehyde, which has a kcat/
Km value in the range of 10
9 min1 M1 for cellular ALDHs. The
slow rate of TBA2 oxidation is potentially problematic, because
TBA2 has to compete with cellular aldehydes to image ALDH
activity in cells. We therefore determined whether cells could
oxidize TBA2. A549 cells were incubated with TBA2 (5 mM) for 2
hours and HPLC was performed on the cell lysates to determine
the conversion of TBA2 into TBC2. As a control, cells were
incubated with TBA2 and the ALDH inhibitor disulramFig. 4 TBA2 can image ALDH activity in cells and is more effective than A
TBA2 or ALDEFLUOR and imaged via fluorescence microscopy. (a) Fluore
of A549 cells treated with TBA2 + disulfiram. (c) Bar graph analysis dem
intensity than the TBA2 + disulfiram group. (d) Fluorescence image of A54
treatedwith ALDEFLUOR+ disulfiram. (f) Bar graph demonstrating that AL
than the ALDEFLUOR + disulfiram treated cells.
This journal is © The Royal Society of Chemistry 2017(100 mM). ESI Fig. S19 and Table S3† demonstrate that the cells
oxidize TBA2 into TBC2. For example, TBA2 was completely
oxidized into TBC2 by A549 cells aer 2 hours of incubation,
and its oxidation was completely inhibited by disulram.TBA2 can image ALDH activity in cells via ow cytometry and
uorescence microscopy
The TBAs have the potential to image ALDH activity in cells via
ow cytometry due to the large spectral shi they generate in
response to ALDH oxidation. To this end, we performed exper-
iments to determine whether TBA2 could measure ALDH
activity in cells via ow cytometry and compared its efficacy to
ALDEFLUOR. A549 cells were treated with either ALDEFLUOR
or TBA2 (1.5 mM or 5 mM) and incubated for 1 hour and 4 hours
respectively, and analyzed via ow cytometry. A549 cells were
also incubated with ALDH inhibitors and either ALDEFLUOR or
TBA2, to establish gates for the ALDH positive cells. Fig. 3
demonstrates that TBA2 can measure ALDH activity in cells via
ow cytometry and is signicantly better than ALDEFLUOR. For
example, A549 cells treated with TBA2 were 93% positive for
ALDH activity, whereas with ALDEFLUOR only 3% of the cells
were ALDH positive, due to the large background uorescence
caused by non-specic accumulation of ALDEFLUOR. TBA2 can
therefore measure ALDH activity in cells via ow cytometry and
should nd numerous applications as a cell culture reagent.
We performed experiments to determine whether TBA2
could image ALDH activity in cells via uorescence microscopy.LDEFLUOR. The ALDH expressing cell line A549 was treated with either
scence image of A549 cells treated with TBA2. (b) Fluorescence image
onstrates that TBA2 treated cells have a 9-fold higher fluorescence
9 cells treated with ALDEFLUOR. (e) Fluorescence image of A549 cells
DEFLUOR treated A549 cells have 1.5 fold higher fluorescence intensity
Chem. Sci., 2017, 8, 7143–7151 | 7147
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View Article OnlineALDH catalyzed oxidation of TBA2 to TBC2 should be readily
imaged by uorescence microscopy, because the emission of
TBC2 is at 520 nm and is signicantly different from that of
TBA2. A549 cells were incubated with TBA2 (5 mM) or TBA2
(5 mM) + disulram (100 mM) for 4 hours, and imaged by uo-
rescence microscopy. As a control, A549 cells were incubated
with ALDEFLUOR (5 mM) or ALDEFLUOR (5 mM) + disulram
(100 mM) for 1 hour and imaged. Fig. 4 demonstrates that TBA2
can image ALDH activity via uorescence microscopy and is
signicantly better than ALDEFLUOR. For example, cells treated
with TBA2 had a 9-fold increase in uorescence compared to
cells treated with TBA2 + disulram. In contrast, cells treated
with ALDEFLUOR only had a 1.5-fold increase in uorescence
over cells treated with ALDEFLUOR + disulram.TBA2 measures ALDH activity in animals using histology
ALDHs are ubiquitously expressed in mammalian tissues and
play an important role in physiology. However, despite their
importance, imaging ALDH activity in vivo has been challenging
due to the lack of imaging dyes. We next determined whether
TBA2 could image ALDH activity in the lungs of mice. TBA2
(0.1 mL, 1 mg kg1) was injected into the intraperitoneal cavity
(IP) using DMSO as a vehicle and aer 4 hours the mice were
sacriced and sections of the lungs were analysed for uores-
cence at an emission wavelength of 520 nm. As a control, mice
were treated with TBA2 and disulram (400 mg kg1). Fig. 5
demonstrates that TBA2 can image ALDH activity in the lungs of
a healthy mouse, as evidenced from histological analysis. For
example, mice treated with TBA2 had a 4-fold higher level of
uorescence emission than mice treated with TBA2 in theFig. 5 TBA2 can measure ALDH activity in the lungs of mice. Fluo-
rescence images of histology sections of lungs made from mice that
were treated with either TBA2 or TBA2 + disulfiram. Mice treated with
TBA2 have a higher fluorescence than mice treated with TBA2 +
disulfiram, demonstrating that TBA2 can image ALDH activity. Bar
graph representation of the fluorescence image analysis of the lungs,
demonstrating that TBA2 can detect ALDH activity in vivo (*p < 0.01).
7148 | Chem. Sci., 2017, 8, 7143–7151presence of disulram. TBA’s ability to image ALDH in vivo has
the potential to signicantly accelerate numerous areas of
research, such as the development of new ALDH inhibitors and
activators, and can also be used to understand how the activity
of the ALDHs is modulated in various pathological conditions.TBA2 images ALDH activity in a plate reader and can be used
to screen for ALDH inhibitors
The over-expression of ALDH is a major cause of drug resistance
in cancer cells, and is also required for maintaining cancer stem
cells and their invasive phenotype.23–27 ALDH inhibitors there-
fore have great promise for improving the treatment of cancer.
However, disulram is the only FDA-approved ALDH inhibitor
available, and is challenging to use in combination with
chemotherapy because it causes liver toxicity, neurotoxicity, and
various other side effects.41–45 There is therefore great interest in
developing new small molecules that can inhibit ALDH activity.
However, developing ALDH inhibitors that are active in cells has
been challenging, because of the lack of assays available for
measuring ALDH activity in live cells. In particular, the inability
to image ALDH activity via a plate reader format has limited the
development of ALDH inhibitors. At present, high throughput
screening (HTS) for ALDH inhibitors has to be done in vitro on
puried enzymes, and cannot be done on cells. Only a small
fraction of test tube positive hits in vitro are effective in cells,
and developing HTS for ALDH inhibitors that can be performed
on cells has the potential to dramatically accelerate the devel-
opment of new ALDH inhibitors.
We performed experiments to determine whether TBA2
could detect ALDH activity in cells in a plate reader format, and
if it had the statistical robustness needed to screen chemical
libraries in cells in a high throughput manner. A549 cells were
selected as the cell line for assay development and validation
because of their well-established expression of ALDH. A549 cells
were plated in 96 well plates and incubated with either TBA2 or
TBA2 and disulram (100 mM) and the uorescence of the cellsFig. 6 TBA2 can be used to develop high throughput cell based
screens for ALDH inhibitors. ALDH activity in A549 cells was measured
in a 96 plate reader, with and without the ALDH inhibitor disulfiram,
and the Z-factor was calculated. Disulfiram (100 mM) + TBA2 (10 mM)
treated A549 cells had a Z-factor of 0.67 in comparison to TBA2
treated cells, and can therefore be used to screen for ALDH inhibitors.
This journal is © The Royal Society of Chemistry 2017
Fig. 7 a,b-unsaturated phenyl cyanoacrylamide fragments inhibit
ALDH activity in A549 cells. A549 cells were either treated with
inhibitor 1 or inhibitor 2 (75 mM) and subsequently were treated with
TBA2 and the increase in fluorescence was observed at 520 nm.
a,b-unsaturated phenyl ethyl/isopropyl cyanoacrylamides inhibit
ALDH activity in cells.
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View Article Onlineat 520 nm was measured via a plate reader. Fig. 6 demonstrates
that TBA2 detects ALDH activity in cells via a plate reader assay
and can be used for developing HTS assays for ALDH inhibitors.
For example, cells treated with TBA2 (10 mM) had a ve-fold
increase in uorescence over cells treated with TBA2
(10 mM) + disulram (100 mM). In addition, the standard devi-
ation of cells treated with TBA2 was small, and the Z-factor for
identifying ALDH inhibitors was 0.67. Thus, TBA2 has the
potential to screen small molecule/fragment based libraries in
cells in a high throughput manner.
Cyanoacrylamide fragments inhibit ALDH activity in cells
Drugs that can irreversibly inhibit ALDH activity have
tremendous potential as therapeutics, because of their long
lasting effects and suitable pharmacokinetic properties.
Moreover, developing irreversible inhibitors against ALDH
should be feasible because ALDHs contain a reactive cysteine
in their active site, which acts as a nucleophile that can be
targeted with activity-based inhibitors.46–48 Therefore, there is
great interest in identifying electrophile fragments that canFig. 8 Cyanoacrylamide fragments sensitize GBM stem cells to temozo
(5 mM), 1 (25 mM), or the combination of temozolomide (5 mM) + 1 (25 mM
thenmeasured. Representative pictures of the spheroids are presented ab
(25 mM) + temozolomide significantly inhibits the ability of GBM stem cel
the presence of DMSO, disulfiram, inhibitor 1 and inhibitor 2. Disulfiram
This journal is © The Royal Society of Chemistry 2017serve as lead candidates for the development of irreversible
ALDH inhibitors.
We therefore screened an electrophile library composed of
1460 electrophiles (obtained from Enamine) against A549 cells
using the cell-based HTS assay developed above. The cells were
treated with members of the library at a 500 mg mL1 concen-
tration for 2.5 hours, incubated with TBA2 (10 mM) for another
2.5 h, and the uorescence intensity at 520 nm was measured.
Compounds generating a 60% suppression in uorescence
intensity relative to the TBA2 treated cells were considered
positive hits. Positive hits were revalidated at lower concentra-
tions to further characterize their activity. Fig. 7 demonstrates
that substituted a,b-unsaturated phenyl cyanoacrylamides are
a pharmacophore with the potential to inhibit ALDH activity in
cells. For example, 3 hits containing the a,b-unsaturated phenyl
cyanoacrylamide pharmacophores were identied, which were
able to inhibit ALDH activity in cells, and had an IC90 compa-
rable to disulram (Fig. 7). a,b-unsaturated phenyl cyanoacry-
lamide fragments are attractive lead compounds for drug
development because of their ability to generate long lasting
reversible inhibitors, and have been widely used for developing
inhibitors against kinases.49–52
We performed experiments to determine whether the hits
identied from our HTS screen, compounds 1 and 2, could
inhibit ALDH activity in glioblastoma multiforme (GBM) tumor
initiating cells and sensitize them to temozolomide (TMZ). For
these experiments, we used GBM cells that were collected from
a clinic, isolated from a male patient who did not respond to
treatment with TMZ. TMZ drug resistance in GBM cells is linked
to the expression of ALDHs, and there is therefore great interest
in developing combination therapeutics composed of TMZ plus
ALDH inhibitors.53 Compounds 1 and 2 have the potential to
sensitize GBM stem cells toward TMZ, and if successful would
provide a much needed alternative to disulram. GBM tumor
initiating cells (50 cells per well) were treated with either TMZ or
TMZ and the inhibitors 1 or 2, and the number of tumor
spheroids formed 10 days aer treatment was measured. Fig. 8a
demonstrates that the ALDH inhibitor fragments 1 and 2
sensitized GBM stem cells to TMZ and dramatically lowered the
number of spheroids formed 10 days aer treatment. Inlomide. (a) GBM stem cells were treated with DMSO, temozolomide
). The number of tumor spheroids formed 10 days after treatment was
ove the bar graph. The combination of inhibitor 1 (25 mM) or inhibitor 2
ls to form tumor spheroids. (b) Viability of tumor initiating cells (TICs) in
is very toxic to TICs, but inhibitors 1 and 2 were not toxic to TICs.
Chem. Sci., 2017, 8, 7143–7151 | 7149
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View Article Onlineaddition, we have performed a MTT assay with TICs using our
leads and disulram. Fig. 8b demonstrates that the inhibitors 1
and 2 have very little toxicity by themselves, but in the presence
of temozolomide they suppress formation of spheroids. There-
fore, they sensitize TICs to temozolomide via inhibition of
ALDH. In contrast, disulram was toxic to TICs at a very low
concentration due to non-specicity, suggesting that the cya-
noacrylamide fragments 1 and 2 have potential as lead candi-
dates for future drug development.
Conclusions
In this report, we have developed a new family of uorescent
probes, termed TBAs, that can image ALDH activity in cells. The
TBAs are composed of a bisthiophene anked by an electron
donor and an aldehyde. The TBAs image ALDH activity via
a uorescence sensing mechanism, based on modulation of
intramolecular charge transfer (ICT). This feature allows these
uorophores to spectrally distinguish between an aldehyde and
a carboxylic acid. We have demonstrated that TBA2 can
measure ALDH in cells via ow cytometry and also enabled the
imaging of ALDH in cells via uorescence microscopy. In
addition, a plate reader-based ALDH assay was developed,
which has the robustness needed to screen chemical libraries.
We screened a large, 1460-entry electrophile library with A549
cells and found three covalent fragments, each containing an
a,b-unsaturated cyanoacrylamide, that were able to inhibit
ALDH activity in cells, and are thus potential lead fragments for
future drug development. The TBAs have the potential to impact
multiple areas of medicine and biology given their ability to
image ALDH activity in cells via ow cytometry and uorescence
microscopy, and via a plate reader.
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